Related Experiment Video

Updated: Jun 22, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Association of body mass index with coronary plaque regression: 6-month prospective study

Shigemasa Tani1, Ken Nagao, Takeo Anazawa

  • 1Department of Cardiology, Nihon University Surugadai Hospital, Tokyo 101-8309, Japan. tanishigem@yahoo.co.jp

Journal of Atherosclerosis and Thrombosis
|June 27, 2009
PubMed

Insights

Higher body mass index (BMI) in patients with coronary artery disease (CAD) reduces the effectiveness of pravastatin in treating atherosclerosis. This suggests personalized treatment strategies for obese CAD patients are needed.

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Obesity is a significant risk factor for coronary artery disease (CAD).
  • Understanding how body mass index (BMI) impacts treatment efficacy is crucial for managing CAD patients.

Purpose of the Study:

  • To investigate the influence of BMI on the effectiveness of pravastatin in reducing coronary atherosclerosis.
  • To explore the relationship between BMI and changes in plaque volume during statin therapy.

Main Methods:

  • Prospective study involving 56 patients with stable CAD.
  • 3D intravascular ultrasound used to assess coronary plaque volume at baseline and after 6 months of pravastatin treatment.

Main Results:

  • Pravastatin treatment significantly reduced plaque volume by 11% (p<0.001).
  • Baseline BMI positively correlated with percent plaque volume (r=0.37, p<0.001).
  • BMI independently predicted changes in plaque volume, indicating reduced treatment efficacy in higher BMI individuals.

Conclusions:

  • Increased BMI attenuates the plaque-reducing effects of pravastatin in CAD patients.
  • Results highlight the need for tailored treatment approaches for obese individuals with coronary artery disease.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...